Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded by StockNews.com to Strong-Buy

StockNews.com upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a buy rating to a strong-buy rating in a research report report published on Saturday morning.

A number of other equities research analysts have also recently weighed in on the company. Barclays upped their price target on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an overweight rating in a report on Thursday, August 1st. Piper Sandler reissued an overweight rating and issued a $20.00 target price (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 13th. UBS Group lifted their price target on Teva Pharmaceutical Industries from $22.00 to $24.00 and gave the stock a buy rating in a research note on Wednesday, July 10th. Bank of America boosted their price objective on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a buy rating in a research report on Thursday, May 30th. Finally, Argus upgraded shares of Teva Pharmaceutical Industries from a hold rating to a buy rating and set a $20.00 target price for the company in a report on Wednesday, July 10th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $18.67.

Teva Pharmaceutical Industries Trading Up 1.3 %

NYSE:TEVA opened at $16.91 on Friday. Teva Pharmaceutical Industries has a 1 year low of $8.06 and a 1 year high of $18.02. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.61 and a current ratio of 0.89. The stock has a fifty day moving average price of $16.79 and a two-hundred day moving average price of $14.84. The stock has a market capitalization of $19.15 billion, a price-to-earnings ratio of -41.23, a PEG ratio of 1.49 and a beta of 0.90.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, May 8th. The company reported $0.46 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. The company had revenue of $3.82 billion during the quarter, compared to analysts’ expectations of $3.70 billion. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries will post 2.35 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Vikki L. Conway sold 15,219 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 15,500 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $16.80, for a total value of $260,400.00. Following the completion of the sale, the chief accounting officer now owns 17,814 shares in the company, valued at approximately $299,275.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Vikki L. Conway sold 15,219 shares of the stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $16.74, for a total transaction of $254,766.06. The disclosure for this sale can be found here. Insiders have sold 574,256 shares of company stock valued at $9,776,999 in the last ninety days. Insiders own 0.55% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Caprock Group LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at $2,150,000. Acadian Asset Management LLC grew its position in Teva Pharmaceutical Industries by 90.8% during the second quarter. Acadian Asset Management LLC now owns 1,124,749 shares of the company’s stock valued at $18,260,000 after acquiring an additional 535,164 shares during the period. Victory Capital Management Inc. increased its stake in Teva Pharmaceutical Industries by 6.0% during the second quarter. Victory Capital Management Inc. now owns 1,906,951 shares of the company’s stock worth $30,988,000 after acquiring an additional 107,909 shares during the last quarter. Range Financial Group LLC raised its holdings in shares of Teva Pharmaceutical Industries by 9.3% in the 2nd quarter. Range Financial Group LLC now owns 61,777 shares of the company’s stock worth $1,004,000 after purchasing an additional 5,278 shares during the period. Finally, TD Asset Management Inc lifted its stake in shares of Teva Pharmaceutical Industries by 1.2% in the 2nd quarter. TD Asset Management Inc now owns 225,109 shares of the company’s stock valued at $3,658,000 after purchasing an additional 2,621 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.